Nosopharm
Philippe VILLAIN-GUILLOT
Chief Executive Officer
Who are we?
NOSOPHARM is an innovative biotechnology company specialized in the research and development of new molecules to combat antimicrobial resistance (AMR). The innovative anti-infective drug discovery platform developed by the company is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus. Nosopharm’s pipeline focuses on the treatment of life- threatening healthcare-associated infections. The most advanced program in the pipeline is NOSO-502, a first-in-class Odilorhabdin antibiotic targeting the very concerning multidrug-resistant pathogens Enterobacteriaceae (ESBL, CRE). Nosopharm is also working on the development of additional first-in-class antimicrobials for the treatment of systemic P. aeruginosa and Candida infections.